Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180Source: DataRank Database

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma is a research paper published in Cancer (2022). On theSindex it has a DataRank of 5.5. It has been cited 265 times, with 100 citing works in its 1-hop citation network.

N/A

5.5DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access265 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02231749

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: hybridTopics (34)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 15%Citation Network 85%

Base Score Contribution

0.838

From this paper's citation signal

Citation Network Contribution

4.7

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology2022387 citations27 referencesContributes 0.221
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis
Cancer Treatment Reviews202317 citations16 referencesContributes 0.181
Immunotherapy in renal cell carcinoma
The Lancet Oncology202312 citations15 referencesContributes 0.171
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Journal of Clinical Oncology202540 citations31 referencesContributes 0.120
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
JCO Clinical Cancer Informatics20248 citations19 referencesContributes 0.116

Authors (25)

David F. McDermott ORCID,Bernard Escudier ORCID,Mauricio Burotto ORCID,Toni K. Choueiri ORCID,Hans J. Hammers ORCID

Live enrichment

PubMed:35383908 PMC:PMC9543316

National Institutes of Health

Grant: P30 CA016672

Memorial Sloan-Kettering Cancer Center

Grant: P30 CA008748

National Institutes of Health

Grant: 2P50CA101942-11A1

DF/HCC Kidney Cancer SPORE

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 3P30CA006516-41S6

CANCER CENTER SUPPORT GRANT

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

Bristol-Myers Squibb

hybridLicense: cc-by-nc-nd

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.34180

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34180

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cncr.34180

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34180

https://pure.au.dk/portal/en/publications/0a9becdb-f346-4c22-a679-2e8c2f921920

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansCarcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFemaleMaleIpilimumabSunitinibNivolumab

Keywords

Long-term follow-upPhase 3Advanced Renal Cell CarcinomaDurable ResponseCheckmate 214Nivolumab Plus IpilimumabDual Checkpoint InhibitionMaleMedizin610Nivolumab/therapeutic useAntineoplastic Combined Chemotherapy ProtocolsSunitinibHumansCarcinoma, Renal CellAntineoplastic Combined Chemotherapy Protocols/adverse effectsOriginal ArticlesIpilimumabKidney NeoplasmsKidney Neoplasms/drug therapyNivolumabCarcinoma, Renal Cell/drug therapyFemale

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 2 of Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation

10.6084/m9.figshare.26682061.v1figshare

Additional file 2 of Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation

10.6084/m9.figshare.26682061figshare

Additional file 1 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.25599852.v1figshare

Additional file 1 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.25599852figshare

Additional file 2 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.25599891.v1figshare

Additional file 2 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.25599891figshare

Additional file 3 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.26706231.v1figshare

Additional file 3 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.26706231figshare

Additional file 4 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.26706234.v1figshare

Additional file 4 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.26706234figshare

Additional file 5 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.26706237.v1figshare

Additional file 5 of PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma

10.6084/m9.figshare.26706237figshare

Additional file 1 of Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation

10.6084/m9.figshare.26682058.v1figshare

Additional file 1 of Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation

10.6084/m9.figshare.26682058figshare

Related Papers (10)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

N/A

6.4DataRank · unranked

ESMO Open(2020)

co-cited

10.1136/esmoopen-2020-001079

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

N/A

3.8DataRank · unranked

Journal of Clinical Investigation(2020)

co-cited

10.1172/jci134915

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

N/A

5.0DataRank · unranked

JAMA Oncology(2020)

co-cited

10.1001/jamaoncol.2019.6152

Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity

Theranostics(2020)

co-cited

10.7150/thno.42243

Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression

N/A

1.9DataRank · unranked

Clinical Cancer Research(2020)

co-cited

10.1158/1078-0432.ccr-19-3283

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

N/A

4.7DataRank · unranked

New England Journal of Medicine(2021)

co-cited

10.1056/nejmoa2103425

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

N/A

4.5DataRank · unranked

Nature Medicine(2021)

co-cited

10.1038/s41591-020-01206-4

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

N/A

5.2DataRank · unranked

The Lancet Oncology(2021)

co-cited

10.1016/s1470-2045(21)00241-2

Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers

N/A

2.1DataRank · unranked

Journal of Clinical Investigation(2021)

co-cited

10.1172/jci152670

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

N/A

0.272DataRank · unranked

Regular and Young Investigator Award Abstracts(2022)

co-cited

10.1136/jitc-2022-sitc2022.0605

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (25)

Funding (7 grants)

Open Access

Topics

Linked Datasets (14)

Annotations (Europe PMC)

Related Papers (10)